PMID- 21775389
OWN - NLM
STAT- MEDLINE
DCOM- 20120206
LR  - 20220317
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 32
IP  - 20
DP  - 2011 Oct
TI  - Patients using vitamin K antagonists show increased levels of coronary 
      calcification: an observational study in low-risk atrial fibrillation patients.
PG  - 2555-62
LID - 10.1093/eurheartj/ehr226 [doi]
AB  - AIMS: Vitamin K antagonists (VKA) are currently the most frequently used drug to 
      prevent ischaemic stroke in atrial fibrillation (AF) patients. However, VKA use 
      has been associated with increased vascular calcification. The aim of this study 
      was to investigate the contribution of VKA use to coronary artery calcification 
      in low-risk AF patients. METHODS AND RESULTS: A prospective coronary calcium scan 
      was performed in 157 AF patients without significant cardiovascular disease (108 
      males; mean age 57 +/- 9 years). A total of 71 (45%) patients were chronic VKA 
      users. The duration of VKA treatment varied between 6 and 143 months (mean 46 
      months). No significant differences in clinical characteristics were found 
      between patients on VKA treatment and non-anticoagulated patients. However, 
      median coronary artery calcium scores differed significantly between patients 
      without and patients with VKA treatment [0, inter-quartile range (IQR) 0-40, vs. 
      29, IQR 0-184; P = 0.001]. Mean coronary calcium scores increased with the 
      duration of VKA use (no VKA: 53 +/- 115, 6-60 months on VKA: 90 +/- 167, and >60 
      months on VKA: 236 +/- 278; P < 0.001). Multivariable logistic regression analysis 
      revealed that age and VKA treatment were significantly related to increased 
      coronary calcium score. CONCLUSION: Patients using VKA show increased levels of 
      coronary calcification. Age and VKA treatment were independently related to 
      increased coronary calcium score.
FAU - Weijs, Bob
AU  - Weijs B
AD  - Department of Cardiology, Maastricht University Medical Centre and Cardiovascular 
      Research Institute Maastricht (CARIM), P.O. Box 5800, 6202 AZ Maastricht, The 
      Netherlands. b.weijs@mumc.nl
FAU - Blaauw, Yuri
AU  - Blaauw Y
FAU - Rennenberg, Roger J M W
AU  - Rennenberg RJ
FAU - Schurgers, Leon J
AU  - Schurgers LJ
FAU - Timmermans, Carl C M M
AU  - Timmermans CC
FAU - Pison, Laurent
AU  - Pison L
FAU - Nieuwlaat, Robby
AU  - Nieuwlaat R
FAU - Hofstra, Leonard
AU  - Hofstra L
FAU - Kroon, Abraham A
AU  - Kroon AA
FAU - Wildberger, Joachim
AU  - Wildberger J
FAU - Crijns, Harry J G M
AU  - Crijns HJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110720
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 12001-79-5 (Vitamin K)
SB  - IM
CIN - Eur Heart J. 2011 Oct;32(20):2473-5. PMID: 21804103
MH  - Aged
MH  - Atrial Fibrillation/*complications
MH  - Coronary Artery Disease/*chemically induced/diagnostic imaging
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multidetector Computed Tomography
MH  - Prospective Studies
MH  - Risk Factors
MH  - Stroke/etiology/*prevention & control
MH  - Vascular Calcification/*chemically induced/diagnostic imaging
MH  - Vitamin K/*antagonists & inhibitors
EDAT- 2011/07/22 06:00
MHDA- 2012/02/07 06:00
CRDT- 2011/07/22 06:00
PHST- 2011/07/22 06:00 [entrez]
PHST- 2011/07/22 06:00 [pubmed]
PHST- 2012/02/07 06:00 [medline]
AID - ehr226 [pii]
AID - 10.1093/eurheartj/ehr226 [doi]
PST - ppublish
SO  - Eur Heart J. 2011 Oct;32(20):2555-62. doi: 10.1093/eurheartj/ehr226. Epub 2011 
      Jul 20.